Literature DB >> 2521325

Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy.

D Feldberg1, J Ashkenazi, D Dicker, A Yeshaya, G A Goldman, D Dicker, J A Goldman.   

Abstract

Since gonadotropin-releasing hormone (GnRH) analogs were introduced into clinical therapeutic use, several side effects directly related to the hypoestrogenic state have been reported. The authors have encountered a rather infrequent complication, namely ovarian cystic formations, when using these compounds for selected in vitro fertilization and embryo transfer (IVF-ET) cases. In 7 of 24 patients with Decapeptyl (D-Trp6-luteinizing hormone-releasing hormone [LH-RH], Ferring, Kiel, FRG) treatment, and in 5 of 22 patients treated with Buserelin (Superfact, Hoechst A.G., Frankfurt, FRG), solitary ovarian cysts developed during the down-regulation phase. Their growth did not change during ovulation induction with menotropins. Although the mechanism of ovarian cyst formation during GnRH agonist treatment is not clear, their presence does not appear to interfere with the fertility of these women.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2521325     DOI： 10.1016/s0015-0282(16)60425-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  9 in total

1.  Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment.

Authors:  S Brett; P Y Yong; K J Thong
Journal:  J Assist Reprod Genet       Date:  2001-06       Impact factor: 3.412

2.  Should fertile people have access to in vitro fertilisation?

Authors:  K Dawson; P Singer
Journal:  BMJ       Date:  1990-01-20

3.  Pituitary down-regulation in IVF cycles: is it necessary to use strict criteria?

Authors:  C Calhaz-Jorge; F Leal; I Cordeiro; H Proença; M Barata; A M Pereira-Coelho
Journal:  J Assist Reprod Genet       Date:  1995-10       Impact factor: 3.412

4.  Conservative management versus aspiration of functional ovarian cysts before ovarian stimulation for assisted reproduction.

Authors:  G E Fiszbajn; R G Lipowicz; L Elberger; A Grabia; S D Papier; S P Brugo Olmedo; C F Chillik
Journal:  J Assist Reprod Genet       Date:  2000-05       Impact factor: 3.412

5.  Comparison of ovarian stimulation regimens for in vitro fertilization (IVE) with and without a gonadotropin-releasing hormone (GnRH) agonist: results of a randomized study.

Authors:  A B van de-Helder; F M Helmerhorst; A Blankhart; R Brand; C Waegemaekers; N Naaktgeboren
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-12

6.  HCG Trigger of GnRH Agonist-Induced Functional Ovarian Cysts Does Not Decrease Clinical Pregnancy Rate in GnRHa Pretreated Frozen Cycles: Evidence From a Retrospective Cohort Study.

Authors:  Hong Zeng; Chen Zhang; Lei Zhang; Nenghui Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-15       Impact factor: 6.055

7.  Functional Ovarian Cysts in Artificial Frozen-Thawed Embryo Transfer Cycles With Depot Gonadotropin-Releasing Hormone Agonist.

Authors:  Hui Ji; Yan Su; Mianqiu Zhang; Xin Li; Xiuling Li; Hui Ding; Li Dong; Shanren Cao; Chun Zhao; Junqiang Zhang; Rong Shen; Xiufeng Ling
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-29       Impact factor: 6.055

8.  Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles.

Authors:  Ozlem Gün Eryılmaz; Esma Sarıkaya; Fatma Nur Aksakal; Sevtap Hamdemir; Muammer Doǧan; Leyla Mollamahmutoǧlu
Journal:  Balkan Med J       Date:  2012-06-01       Impact factor: 2.021

9.  Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: a retrospective cohort study.

Authors:  Yingfen Ying; Tanchu Yang; Huina Zhang; Chang Liu; Junzhao Zhao
Journal:  PeerJ       Date:  2019-04-29       Impact factor: 2.984
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.